Semaglutide

Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), sharing about 94% sequence homology with the native hormone. Structural modifications — including a fatty-acid side chain that promotes albumin binding and resistance to DPP-4 enzymatic degradation — extend its half-life to roughly one week, enabling once-weekly dosing. As a selective GLP-1 receptor agonist, it stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic and brainstem appetite-regulation centers to increase satiety and reduce food intake.

Semaglutide has one of the largest phase 3 clinical programs among metabolic peptides, spanning Novo Nordisk's STEP program (obesity/overweight) and SUSTAIN program (type 2 diabetes). STEP 1 (Wilding et al., NEJM 2021) reported a mean 14.9% body-weight reduction at 68 weeks versus placebo in adults with obesity or overweight without diabetes. SUSTAIN-6 (Marso et al., NEJM 2016) demonstrated a 26% relative risk reduction in major adverse cardiovascular events among type 2 diabetes patients at high cardiovascular risk. This body of evidence underlies FDA and EMA approval for both glycemic control and chronic weight management.

Educational overview only — no dosing instructions in the public hub.

Common adverse effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, abdominal pain — generally dose-dependent and most pronounced during dose escalation. Serious risks documented in clinical trials include acute pancreatitis, gallbladder disease (cholelithiasis/cholecystitis), acute kidney injury (often secondary to GI-related fluid loss), worsening of diabetic retinopathy in patients with pre-existing diabetic eye disease, and a boxed warning for thyroid C-cell tumors based on rodent studies (human relevance unconfirmed; contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2). Non-prescription, 'research use only,' or compounded semaglutide products carry additional, unquantified risks: uncertain dosing accuracy, impurities, and no clinical supervision to manage side effects or contraindications.

Semaglutide is a genuine prescription biologic with a narrow margin between effective dosing and gastrointestinal intolerance, making source and formulation integrity critical. Regulatory agencies have issued advisories about compounded or 'research-grade' semaglutide — including salt forms (e.g., semaglutide sodium or acetate) not used in the approved drug — linked to dosing errors and adverse events. Content here reflects the approved pharmaceutical product as studied in registered trials, not gray-market material of unverified composition or purity.

Approved prescription medication (FDA and EMA) marketed as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management), requiring a physician's prescription and medical supervision. Non-prescription, 'research use only,' or compounded semaglutide products sold outside this regulatory framework are not approved by FDA/EMA for human use, lack quality assurance, and carry additional risks when used without medical supervision.